21.07
-0.73(-3.35%)
Currency In USD
| Previous Close | 21.8 |
| Open | 21.5 |
| Day High | 22.02 |
| Day Low | 20.76 |
| 52-Week High | 30 |
| 52-Week Low | 3.42 |
| Volume | 568,264 |
| Average Volume | 799,186 |
| Market Cap | 986.26M |
| PE | -6.07 |
| EPS | -3.47 |
| Moving Average 50 Days | 21.69 |
| Moving Average 200 Days | 17.75 |
| Change | -0.73 |
If you invested $1000 in UroGen Pharma Ltd. (URGN) since IPO date, it would be worth $1,507.15 as of February 21, 2026 at a share price of $21.07. Whereas If you bought $1000 worth of UroGen Pharma Ltd. (URGN) shares 5 years ago, it would be worth $902.36 as of February 21, 2026 at a share price of $21.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 04, 2026 1:00 PM GMT
PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management wi
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
GlobeNewswire Inc.
Jan 05, 2026 1:00 PM GMT
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patient
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will prese